Cargando…
Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D(3)) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis
BACKGROUND: 2-Methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D(3) (DP001 or 2MD) is a novel, potent 1α-hydroxylated vitamin D analog that binds to the vitamin D receptor and suppresses parathyroid hormone synthesis and secretion with potential for an improved safety profile compared to existing activ...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694423/ https://www.ncbi.nlm.nih.gov/pubmed/28905271 http://dx.doi.org/10.1007/s40268-017-0210-z |